Frontotemporal Lobar Degeneration: Clinical Trials

10 trials for Frontotemporal Lobar Degeneration, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 2 recruiting. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 5, Terminated 3, Recruiting 2

Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Phase 3RecruitingNovartis Pharmaceuticals3002026-06-032026-10-15
Continuation Study for Latozinemab
Latozinemab - Neurodegenerative Diseases
Phase 3TerminatedAlector Inc.172023-12-082026-01-21
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
[18F]-PI-2620 - Frontotemporal Lobar Degeneration, Alzheimer Disease
Phase 3RecruitingUniversity of Pennsylvania722022-09-192026-09-21
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001 - Frontotemporal Dementia
Phase 3TerminatedAlector Inc.1192020-07-232026-09-21
The Healthy Patterns Sleep Study
Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease
Phase 3CompletedUniversity of Pennsylvania4212016-05-012024-07-26
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
LMTM - Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Phase 3TerminatedTauRx Therapeutics Ltd9132014-08-012023-05-24
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
TRx0237, Placebo - Behavioral Variant Frontotemporal Dementia (bvFTD)
Phase 3CompletedTauRx Therapeutics Ltd2202013-05-012018-03-14
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
memantine hydrochloride - Frontotemporal Dementia
Phase 3CompletedTiffany Chow, MD172007-10-012012-06-04
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid
doxycycline, rifampicin, Placebo matched to doxycycline - Alzheimer's Disease
Phase 3CompletedHamilton Health Sciences Corporation1002007-02-012018-03-19
COGNIShunt® System for Alzheimer's Disease
The COGNIShunt® System - Alzheimer Disease
Phase 3CompletedEunoe2502001-01-012006-09-12

Narrower conditions

Frontotemporal Dementia (6)  ·  Alzheimer Disease (5)  ·  Pick Disease of the Brain (4)  ·  Dementia (3)  ·  Cognitive Dysfunction (2)  ·  Neurodegenerative Diseases (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Brain Diseases (1)  ·  Chronobiology Disorders (1)  ·  Dementia, Vascular (1)  ·  Disorders of Excessive Somnolence (1)  ·  Memory Disorders (1)  ·  Neurocognitive Disorders (1)  ·  Plaque, Amyloid (1)

Broader conditions

Central Nervous System Diseases (10)  ·  Mental Disorders (10)  ·  Nervous System Diseases (10)  ·  Brain Diseases (9)  ·  Neurocognitive Disorders (9)  ·  Neurodegenerative Diseases (8)  ·  Dementia (7)  ·  Metabolic Diseases (7)  ·  Nutritional and Metabolic Diseases (7)  ·  Proteostasis Deficiencies (7)  ·  TDP-43 Proteinopathies (7)  ·  Tauopathies (6)  ·  Frontotemporal Dementia (3)  ·  Pathological Conditions, Signs and Symptoms (3)

Interventions

((18)F)PI-2620 (1)  ·  Doxycycline (1)  ·  Memantine (1)  ·  Rifampin (1)  ·  hydromethylthionine (1)

Sponsors

Alector Inc. (2)  ·  TauRx Therapeutics Ltd (2)  ·  University of Pennsylvania (2)  ·  Eunoe (1)  ·  Hamilton Health Sciences Corporation (1)  ·  Novartis Pharmaceuticals (1)  ·  Tiffany Chow, MD (1)

Countries

United States (7)  ·  Canada (6)  ·  Germany (5)  ·  Netherlands (5)  ·  United Kingdom (5)  ·  Australia (4)  ·  Belgium (4)  ·  France (4)  ·  Italy (4)  ·  Spain (4)  ·  Croatia (2)  ·  Portugal (2)  ·  Romania (2)  ·  Singapore (2)  ·  South Korea (2)

Top investigators

Alwin Cunje, MD, PhD (1)  ·  Brandon M Kucher, PhD (1)  ·  David D Cowan, MD, FRCPC (1)  ·  Dawn McGuire, MD, Chief Scientific Officer (1)  ·  Jeffrey S Phillips (1)  ·  Nancy A. Hodgson (1)  ·  Tiffany W Chow, MD (1)  ·  Tim I Standish, MA (1)  ·  Tricia KW Woo, MD, FRCPC (1)  ·  William Molloy, MB, FRCPC (1)

Results publications

PMID 21792308, PMID 22674572, PMID 24819148, PMID 33853394, PMID 34344312

NIH funding

2023 (1), R01NR015226 (1)